What is Moteson?
Treating itching, redness, and swelling of many skin conditions.
Moteson is a topical corticosteroid. It works by reducing inflammatory reactions and modifying immune reactions in the body.
Moteson indications
Treatment of Allergic Rhinitis
Moteson Nasal Spray 50 mcg is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis, in adults and pediatric patients 2 years of age and older.
Treatment of Nasal Congestion Associated with Seasonal Allergic Rhinitis
Moteson Nasal Spray 50 mcg is indicated for the relief of nasal congestion associated with seasonal allergic rhinitis, in adults and pediatric patients 2 years of age and older.
Prophylaxis of Seasonal Allergic Rhinitis
Moteson Nasal Spray 50 mcg is indicated for the prophylaxis of the nasal symptoms of seasonal allergic rhinitis in adult and adolescent patients 12 years and older.
Treatment of Nasal Polyps
Moteson Nasal Spray 50 mcg is indicated for the treatment of nasal polyps in patients 18 years of age and older.
How should I use Moteson?
Use Moteson as directed by your doctor. Check the label on the medicine for exact dosing instructions. Check the label on the medicine for exact dosing instructions.
- Shake well before each use.
- Apply a small amount of Moteson to the affected area once a day. Gently rub the medicine in until it is evenly distributed. Wash your hands immediately after using Moteson, unless your hands are part of the treated area.
- If you miss a dose of Moteson, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Moteson.
Moteson dosage
Apply a thin film of Moteson (Moteson ointment) to the affected skin areas once daily. Moteson (Moteson ointment) may be used in pediatric patients 2 years of age or older. Since safety and efficacy of Moteson (Moteson ointment) have not been adequately established in pediatric patients below 2 years of age, its use in this age group is not recommended..
As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.
Safety and efficacy of Moteson (Moteson ointment) in pediatric patients for more than 3 weeks have not been established.
Moteson (Moteson ointment) should not be used with occlusive dressings unless directed by a physician. Moteson (Moteson ointment) should not be applied in the diaper area if the child still requires diapers or plastic pants as these garments may constitute occlusive dressing.
How supplied
Moteson (Moteson ointment), 0.1%, is supplied in 15-g (NDC 0085-0370-01) and 45-g (NDC 0085-0370-02) tubes; boxes of one.
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F)
ELOCON® brand of Moteson ointment, Ointment 0.1%, For Dermatologic Use Only. Not for Ophthalmic Use. SP Schering Corporation, Kenilworth, NJ 07033 USA. Rev. 9/18/02. FDA Rev date: 12/15/2002
Moteson interactions
See also:
What other drugs will affect Moteson?
Possible food and drug interactions when taking Moteson:
No interactions have been noted.
Moteson side effects
See also:
What are the possible side effects of Moteson?
In controlled clinical studies involving 812 patients, the incidence of adverse reactions associated with the use of Moteson (Moteson ointment) was 4.8%. Reported reactions included burning, pruritus, skin atrophy, tingling/stinging, and furunculosis. Reports of rosacea associated with the use of Moteson (Moteson ointment) have been received. In controlled clinical studies (n=74) involving pediatric patients 2 to 12 years of age, the incidence of adverse experiences associated with the use of ELOCON Cream is approximately 7%. Reported reactions included stinging, pruritus, and furunculosis.
The following adverse reactions were reported to be possibly or probably related to treatment with Moteson (Moteson ointment) during a clinical study, in 5% of 63 pediatric patients 6 months to 2 years of age: decreased glucocorticoid levels, 1; an unspecified skin disorder, 1; and a bacterial skin infection, 1. The following signs of skin atrophy were also observed among 63 patients treated with Moteson (Moteson ointment) in a clinical study: shininess 4, telangiectasia 1, loss of elasticity 4, loss of normal skin markings 4, thinness 1. Striae and bruising were not observed in this study.
The following additional local adverse reactions have been reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, striae, and miliaria.
Moteson contraindications
See also:
What is the most important information I should know about Moteson?
Moteson (Moteson ointment) is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation.
Active ingredient matches for Moteson:
Mometasone furoate in Indonesia.
List of Moteson substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Mometasone Lotion | |
| Mometasone Nasal Spray | |
| Mometasone Ointment | |
| Momexin | |
| MOMOZ-S (India) | |
| 15g (Unichem) | $ 1.10 |
| Momoz-S Mometasone furoate 0.1 %, Salicylic acid 5 %. OINT / 15g (Unichem) | $ 1.10 |
| MOMOZ-S oint 15g (Unichem) | $ 1.10 |
| Momoz-S Mometasone furoate 0.1 %, Salicylic acid 5 %. OINT / 15g (Unichem) | $ 1.10 |
| MOPITUS (India) | |
| 0.1 % x 10g (Auriga) | $ 0.90 |
| Mopitus 0.1% CRM / 10g (Auriga) | $ 0.90 |
| MOPITUS cream 0.1 % x 10g (Auriga) | $ 0.90 |
| Mopitus 0.1% CRM / 10g (Auriga) | $ 0.90 |
| MOPITUS-S (India) | |
| 10g (Auriga) | $ 1.02 |
| Mopitus-S Mometasone furoate 0.1 %, Salicylic acid 3 %. CRM / 10g (Auriga) | $ 1.02 |
| MOPITUS-S cream 10g (Auriga) | $ 1.02 |
| Mopitus-S Mometasone furoate 0.1 %, Salicylic acid 3 %. CRM / 10g (Auriga) | $ 1.02 |
| MOST (India) | |
| 0.1 % w/w x 15g (Daksh) | $ 1.11 |
| 0.1 % w/w x 5g (Daksh) | $ 0.70 |
| Most 0.1% w/w OINT / 15g (Daksh) | $ 1.11 |
| Most 0.1% w/w OINT / 5g (Daksh) | $ 0.70 |
| MOST oint 0.1 % w/w x 15g (Daksh) | $ 1.11 |
| MOST oint 0.1 % w/w x 5g (Daksh) | $ 0.70 |
| Most 0.1% w/w OINT / 15g (Daksh) | $ 1.11 |
| Most 0.1% w/w OINT / 5g (Daksh) | $ 0.70 |
| MOTOBACT (India) | |
| MOTOBACT cream 0.1 % x 10g (Intra Life (Cutis)) | $ 0.65 |
| Nasonex Aqueous Nasal Spray (Vietnam) | |
| Nasonex Aqueous Nasal Spray 50 mcg/1 dose x 60 lieГ u | |
| Nasonex Aqueous Nasal Spray 50 mcg/1 dose x 140 lieГ u | |
| Nasonex 安鼻適 (Hongkong) | |
| Nasonex nasal spray 0.05 % 60 metered dose x 1's (MSD) | |
| Nasonex nasal spray 0.05 % 140 metered dose x 1's (MSD) | |
| Nazolux 0.05% | |
| Nazolux 0.1% | |
| RHOMENTUM (India) | |
| 0.1 % x 5g (Cure Quick) | $ 0.57 |
| Rhomentum 0.1% OINT / 5g (Cure Quick) | $ 0.57 |
| RHOMENTUM CREAM 1 tube / 5 GM cream each (Cure Quick) | $ 0.64 |
| RHOMENTUM oint 0.1 % x 5g (Cure Quick) | $ 0.57 |
| Rhomentum 0.1% OINT / 5g (Cure Quick) | $ 0.57 |
| Rhomentum NA Cream (Cure Quick) | $ 0.64 |
| SENSICORT-BF (India) | |
| 5g (Zuventus (Zuvista)) | $ 1.14 |
| Sensicort-BF Mometasone furoate 0.1 %, Mupirocin 2 %, miconazole 2%/5 gm. OINT / 5g (Zuventus (Zuvista)) | $ 1.14 |
| SENSICORT-BF oint 5g (Zuventus (Zuvista)) | $ 1.14 |
| Sensicort-BF Mometasone furoate 0.1 %, Mupirocin 2 %, miconazole 2%/5 gm. OINT / 5g (Zuventus (Zuvista)) | $ 1.14 |
See 124 substitutes for Moteson | |
References
- DailyMed. "FORMOTEROL FUMARATE; MOMETASONE FUROATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "mometasone furoate". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DTP/NCI. "Nasonex: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.". https://dtp.cancer.gov/dtpstandard/s... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Moteson are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Moteson. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yet1 consumer reported age
| Users | % | ||
|---|---|---|---|
| 1-5 | 1 | 100.0% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
